Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women

Obesity

Volumn 17, Issue 6, 2009, Pages 1124-1128

  Simón, Inmaculada ^a   Escoté, Xavier ^a   Vilarrasa, Nria ^b   Gómez, José ^b   Fernández Real, José M ^c   Megía, Ana ^a   Gutiérrez, Cristina ^a   Gallart, Lluis ^a   Masdevall, Carles ^b   Vendrell, Joan ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN, HUMAN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; INTERLEUKIN 18; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BLOOD; FEMALE; HUMAN; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; MORBID OBESITY; PATHOPHYSIOLOGY; STOMACH BYPASS; TIME; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FATTY ACID-BINDING PROTEINS; FEMALE; GASTRIC BYPASS; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-18; MIDDLE AGED; OBESITY, MORBID; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 67650479007     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.665     Document Type: Article

References (28)

1. Grunfy SM, Brewer HB Jr, Cleeman JI et al. Definition of Metabolic Syndrome: report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-438.
2. Tracy RR Is visceral fat the "enemy within"? Arterioscler Thromb Vasc Biol 2001;21:881-883.
3. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005;56:45-62.
4. Ferroni P, Basili S, Falco A et al. Inflammation, insulin resistance and obesity. Curr Atheroscler Rep 2004;6:424-431.
5. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-2556.
6. Mora S, Pressin JE. An adipocentric view of signalling and intracellular trafficking. Diabetes Metab Res Rev 2002;18:345-356.
7. Das UN. Is obesity an inflammatory condition? Nutrition 2001;7:953-966.
8. Cottam DR, Schaefer PA, Shaftan GW et al. Effect of surgically-induced weight loss on leukocyte indicators of chronic inflammation in morbid obesity. Obes Surg 2002;12:335-342.
9. Vendrell J, Broch M, Vilarrasa N et al. Resistin, adiponectin, ghrelin, leptin and proinflammatory cytokines: relationships in obesity. Obes Res 2004;12:962-971.
10. Maeda K, Cao H, Kono K et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005;1:107-119.
11. Xu A, Wang Y, Yu SJ et al. Adipocyte fatty acid-binding protein is a plasma biomarker associated with obesity and Metabolic Syndrome. Clin Chem 2006;52:405-413.
12. Maeda K. Role of adiponectin and adipocyte fatty acid binding protein in the metabolic syndrome. Diabetes Res Clin Pract 2007;77S:S17-S22.
13. Makowski L, Hotamisligil GS. Fatty acid binding-proteins - the evolutionary crossroads of inflammatory and metabolic responses. J Nutr 2004;134:2464S-2468S.
14. Hotamisligil GS, Johnson RJ, Distel RJ et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996;274:1377-1379.
15. Boord JB, Maeda K, Makowski L et al. Adipocyte fatty acid binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002;22: 1686-1691.
16. Xu A, Tso AW, Cheung BM et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5 year prospective study. Circulation 2007;115:1537-1543.
17. Tso A, Xu AW, Sham P et al. Serum adipocyte fatty acid-binding protein as a new biomarker predicting the development of type 2 diabetes. Diabetes Care 2007;30:2667-2672.
18. Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in Caucasian population: a new marker of metabolic syndrome? Eur J Clin Invest 2006;36:621-625.
19. Tuncman G, Erbay E, Horn X et al. A genetic variant at the fatty acid binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes and cardiovascular disease. Proc Natl Acad Sci USA 2006;103:6970-6975.
20. Capella RF, Capella JR Reducing early technical complications in gastric bypass surgery. Obes Surg 1997;7:149-156.
21. Friedewald WT, Levy Rl, Fredickson DS. Estimation of the concentration of the low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
22. Reinehr T, Stoffel-Wagner B, Roth CL. Adipocyte fatty acid-binding protein in obese children before and after weight loss. Metabolism 2007;56: 1735-1741.
23. -/- mice. Am J Physiol Endocrinol Metab 2005;288:E187-E193.
24. Fisher RM, Hoffstedt J, Hotamisligil GS et al. Effects of obesity and weight loss on the expression of proteins involved in fatty acid metabolism in human adipose tissue. Int J Obes Relat Metab Disord 2002;26:1379-1385.
25. Shen WJ, Liang Y, Hong R et al. Characterization of the functional interaction of adipocyte lipid-binding protein with hormone-sensitive lipase. J Biol Chem 2001;276:49443-49448.
26. Haider DG, Schindler K, Bohdjalian A et al. Plasma adipocyte and epidermal fatty acid-binding protein is reduced after weight loss in obesity. Diabetes Obes Metab 2007;9:761-763.
27. Engl J, Ciardi C, Tatarczyk T et al. A-FABP - a biomarker associated with the metabolic syndrome and/or an indicator of weight change? Obesity (Silver Spring) 2008;16:1838-42.
28. Lee H, Kim D, Lee S, Nam K, Kim E. Initial evaluation of laparoscopic Roux-en-Y gastric bypass and adjustable gastric banding in Korea: a single institution study. Obes Surg 2008;e-pub ahead of print 29 April 2008.